Demographic | Age |
Sex | |
SLE | Age of diagnosis and disease duration |
Raynaud's phenomenon | |
Telangiectasia | |
System involvements: pleuritis, pericarditis and interstitial lung disease | |
Immunological abnormalities: anti-RNP antibodies, anti-SSA/Ro antibodies and anticardiolipin antibodies | |
SLEDAI-2K (supplementary appendix S1) | |
Nail-fold video capillaroscopy: microangiopathy (“early”, “active” and “late”) | |
Present and past treatment modalities and the corresponding duration for SLE | |
Cardiovascular data | |
Risk factors | Hypertension, diabetes mellitus and hyperlipidaemia |
Diseases | Coronary artery disease, peripheral artery disease, stroke, myocardial infarction, heart failure, atrial fibrillation and other conduction abnormalities |
Renal function | Serum urea, serum creatinine and estimated glomerular filtration rate |
Lung function test | Diffusion capacity of the lung for carbon monoxide |
SLE: systemic lupus erythematosus; RNP: ribonucleoprotein; SSA: Sjögren's syndrome A; SLEDAI-2K: SLE disease activity index-2K score.